Circulating Tumor DNA Guided Treatment Monitoring in Advanced Lung Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorZealand University Hospital
About this trial
The study is a prospective randomized interventional study including patients with advanced non-small cell lung cancer, receiving immunotherapy, with the aim of optimizing treatment monitoring. The study aims to investigate the clinical utility of liquid biopsy monitoring in order to reduce the numbers of inefficient treatments and needless toxicity - and to explore the cost-effectiveness and cost-utility of introducing liquid biopsy monitoring in daily clinical practice.
Eligibility criteria
Qualifiers
Newly diagnosed, histologically verified, Non-Small Cell Lung Cancer (NSCLC)
Advanced or locally advanced disease without curative intended treatment options
Age > 18 years
Eastern Cooperative Oncology Group (ECOG) score of Performance Status (PS) 0-1
Disqualifiers
Targetable alterations in EGFR, ALK or ROS-1
Other active cancers
Trial design
Treatments tested in this trial
- Circulating tumor DNA treatment monitoring
Treatment groups
350 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov